Ken Griffin
ITRM

Ken Griffin’s Iterum Therapeutics ITRM Stock Holding History

Ken Griffin’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,207
Closed -$37.5K – 15019
2024
Q4 		$37.5K Buy
+21,207
New +$33.2K ﹤0.01% 12666
2023
Q4 		– Sell
-19,566
Closed -$16.2K – 14771
2023
Q3 		$16.2K Buy
+19,566
New +$18.6K ﹤0.01% 12785
2022
Q2 		– Sell
-3,368
Closed -$18K – 13481
2022
Q1 		$18K Buy
3,368
+1,875
+126% +$10.8K ﹤0.01% 13272
2021
Q4 		$9K Buy
+1,493
New +$11.5K ﹤0.01% 13672
2021
Q3 		– Sell
-4,624
Closed -$160K – 14222
2021
Q2 		$160K Sell
4,624
-4,511
-49% -$97.8K ﹤0.01% 12421
2021
Q1 		$193K Sell
9,135
-1,554
-15% -$37K ﹤0.01% 11748
2020
Q4 		$159K Buy
10,689
+9,932
+1,312% +$116K ﹤0.01% 9908
2020
Q3 		$12K Buy
+757
New +$10.1K ﹤0.01% 9928

Other funds holding ITRM

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Ken Griffin's ITRM Position: Q1 2025 in Review

Ken Griffin sold out of Iterum Therapeutics (ITRM) in Q1 2025, closing a stake of 21,207 shares — an estimated $37.5K sold.

Ken Griffin first reported a position in ITRM in Q3 2020 and held it in 8 quarters. The position peaked at $193K in Q1 2021. 20 funds tracked by Wall St. Rank hold ITRM as of Q1 2025.

  • Ken Griffin reported no remaining Iterum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ken Griffin sold 21,207 Iterum Therapeutics shares in Q1 2025, an estimated $37.5K.
  • Ken Griffin first reported a position in Iterum Therapeutics in Q3 2020 and held it in 8 quarters.
  • Ken Griffin's Iterum Therapeutics position peaked at $193K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.